These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

140 related items for PubMed ID: 9370178

  • 1. A randomized trial comparing cyclosporine induction with sequential therapy in renal transplant recipients.
    Kasiske BL, Johnson HJ, Goerdt PJ, Heim-Duthoy KL, Rao VK, Dahl DC, Ney AL, Andersen RC, Jacobs DM, Odland MD.
    Am J Kidney Dis; 1997 Nov; 30(5):639-45. PubMed ID: 9370178
    [Abstract] [Full Text] [Related]

  • 2. Excellent outcome with a calcium channel blocker-supplemented immunosuppressive regimen in cadaveric renal transplantation. A potential strategy to avoid antibody induction protocols.
    Suthanthiran M, Haschemeyer RH, Riggio RR, Adubor C, Friedman GS, Cheigh JS, Wang JC, Fotino M, Stubenbord WT, Saal SD.
    Transplantation; 1993 May; 55(5):1008-13. PubMed ID: 8497873
    [Abstract] [Full Text] [Related]

  • 3. Primary immunosuppression with mycophenolate mofetil and antithymocyte globulin for kidney transplant recipients of a suboptimal graft.
    Grinyó JM, Gil-Vernet S, Seron D, Hueso M, Fulladosa X, Cruzado JM, Moreso F, Fernandez A, Torras J, Riera L, Castelao AM, Alsina J.
    Nephrol Dial Transplant; 1998 Oct; 13(10):2601-4. PubMed ID: 9794567
    [Abstract] [Full Text] [Related]

  • 4. Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection.
    Sollinger H, Kaplan B, Pescovitz MD, Philosophe B, Roza A, Brayman K, Somberg K.
    Transplantation; 2001 Dec 27; 72(12):1915-9. PubMed ID: 11773888
    [Abstract] [Full Text] [Related]

  • 5. Prevention of acute rejection with antithymocyte globulin, avoiding corticosteroids, and delaying cyclosporin after renal transplantation.
    Cantarovich D, Giral-Classe M, Hourmant M, Dantal J, Blancho G, Lerat L, Moreau A, Soulillou JP.
    Nephrol Dial Transplant; 2000 Oct 27; 15(10):1673-6. PubMed ID: 11007839
    [Abstract] [Full Text] [Related]

  • 6. Single bolus antithymocyte globulin versus basiliximab induction in kidney transplantation with cyclosporine triple immunosuppression: efficacy and safety.
    Kyllönen LE, Eklund BH, Pesonen EJ, Salmela KT.
    Transplantation; 2007 Jul 15; 84(1):75-82. PubMed ID: 17627241
    [Abstract] [Full Text] [Related]

  • 7. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
    Lü TM, Yang SL, Wu WZ, Tan JM.
    Chin Med J (Engl); 2011 Mar 15; 124(5):664-8. PubMed ID: 21518554
    [Abstract] [Full Text] [Related]

  • 8. Outcome of cadaveric renal transplantation by induction treatment in the cyclosporine era.
    Hariharan S, Alexander JW, Schroeder TJ, First MR.
    Clin Transplant; 1996 Apr 15; 10(2):186-90. PubMed ID: 8664516
    [Abstract] [Full Text] [Related]

  • 9. Beneficial effect of concomitant induction with antilymphoblast globulin, cyclosporine, and steroids on long-term renal allograft outcome.
    Koga A, Moreso FJ, Seron D, Gil-Vernet S, Cruzado JM, Castelao AM, Grinyó JM.
    Transplant Proc; 2004 Jun 15; 36(5):1305-7. PubMed ID: 15251318
    [Abstract] [Full Text] [Related]

  • 10. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.
    Sollinger HW.
    Transplantation; 1995 Aug 15; 60(3):225-32. PubMed ID: 7645033
    [Abstract] [Full Text] [Related]

  • 11. Cadaveric kidney transplantation under prophylactic polyclonal antibody immunosuppression with anti-lymphoblast globulin versus anti-thymocyte globulin.
    Indudhara R, Novick AC, Hodge E, Goormastic M, Papajcik D, Mastroianni B, Cook D.
    Urology; 1996 Jun 15; 47(6):807-12. PubMed ID: 8677568
    [Abstract] [Full Text] [Related]

  • 12. Observations on quadruple immunosuppression maintenance therapy using rapamycin, low-dose cyclosporine, mycophenolate mofetil, and prednisone following ATG induction.
    Khauli RB, Houjaij A, Sawah S, El-Hout Y, Medawwar W, Hussein M, Habbal A, Daouk M, Uwaydah M, Maacaron H, Abdelnoor A.
    Transplant Proc; 2005 Sep 15; 37(7):3031-3. PubMed ID: 16213295
    [Abstract] [Full Text] [Related]

  • 13. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Rapamune Study Group.
    Kahan BD, Julian BA, Pescovitz MD, Vanrenterghem Y, Neylan J.
    Transplantation; 1999 Nov 27; 68(10):1526-32. PubMed ID: 10589950
    [Abstract] [Full Text] [Related]

  • 14. Single-center analysis of 468 first cadaveric kidney allografts with a uniform ATG-CsA sequential therapy.
    Giral M, Taddei C, Nguyen JM, Dantal J, Hourmant M, Cantarovich D, Blancho G, Ancelet D, Soulillou JP.
    Clin Transpl; 1996 Nov 27; ():257-64. PubMed ID: 9286575
    [Abstract] [Full Text] [Related]

  • 15. Improved renal function in sirolimus-treated renal transplant patients after early cyclosporine elimination.
    Gonwa TA, Hricik DE, Brinker K, Grinyo JM, Schena FP, Sirolimus Renal Function Study Group.
    Transplantation; 2002 Dec 15; 74(11):1560-7. PubMed ID: 12490789
    [Abstract] [Full Text] [Related]

  • 16. A randomized trial with steroids and antithymocyte globulins comparing cyclosporine/azathioprine versus tacrolimus/mycophenolate mofetil (CATM2) in renal transplantation.
    Vacher-Coponat H, Moal V, Indreies M, Purgus R, Loundou A, Burtey S, Brunet P, Moussi-Frances J, Daniel L, Dussol B, Berland Y.
    Transplantation; 2012 Feb 27; 93(4):437-43. PubMed ID: 22228415
    [Abstract] [Full Text] [Related]

  • 17. A prospective randomized comparison of quadruple versus triple therapy for first cadaver transplants with immediate function.
    Slakey DP, Johnson CP, Callaluce RD, Browne BJ, Zhu YR, Roza AM, Adams MB.
    Transplantation; 1993 Oct 27; 56(4):827-31. PubMed ID: 8212201
    [Abstract] [Full Text] [Related]

  • 18. Combination treatment of low dose Anti-Thymocyte Globulin (ATG), Rituximab and high dose Sirolimus as induction agents in immune-conditioned recipients.
    Ravichandran P, Natrajan T, Jaganathan R.
    Int Immunopharmacol; 2006 Dec 20; 6(13-14):1973-6. PubMed ID: 17161350
    [Abstract] [Full Text] [Related]

  • 19. Mycophenolate mofetil, ATG, and cyclosporine in the induction treatment of renal transplant recipients minimizes the incidence of acute rejection episodes.
    Puig JM, Lloveras J, Fernández-Crespo P, Mir M, Marcas LI, Manresa JM, Masramón J.
    Transplant Proc; 1998 Aug 20; 30(5):2226-7. PubMed ID: 9723449
    [No Abstract] [Full Text] [Related]

  • 20. Results of the Minnesota randomized prospective trial of cyclosporine versus azathioprine-antilymphocyte globulin for immunosuppression in renal allograft recipients.
    Sutherland DE, Fryd DS, Strand MH, Canafax DM, Ascher NL, Payne WD, Simmons RL, Najarian JS.
    Am J Kidney Dis; 1985 Jun 20; 5(6):318-27. PubMed ID: 3893106
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.